Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.64 |
| ▸ | MAOB | P27338 | 3/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CHAT | P28329 | 2/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.41 |
| ▸ | RELA | Q04206 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4159222 | 1.00 | NFE2L2 (0.64) | NFE2L2MAOBCYP11B1CYP11B2CYP19A1 | |
| SCHEMBL813058 | 1.00 | NFE2L2 (0.64) | NFE2L2MAOBCYP11B1CYP11B2CYP19A1 | |
| SCHEMBL13790261 | 0.97 | NFE2L2 (0.67) | NFE2L2MAOBCYP11B1CYP11B2CYP19A1 | |
| SCHEMBL13790298 | 0.87 | NFE2L2 (0.46) | NFE2L2CYP11B1 | |
| SCHEMBL13790300 | 0.87 | NFE2L2 (0.46) | NFE2L2CYP11B1 | |
| SCHEMBL21030088 | 0.78 | NFE2L2 (1.00) | NFE2L2MAOBCYP19A1MAOACHAT | |
| (Z)-1,2-Diphenylethene SCHEMBL9134296 | 0.78 | MAOB (0.73) | NFE2L2MAOBCYP11B1CYP11B2CYP19A1 | |
| (Z)-1,2-Diphenylethene SCHEMBL22712863 | 0.78 | MAOB (0.73) | NFE2L2MAOBCYP11B1CYP11B2CYP19A1 | |
| (Z)-1,2-Diphenylethene SCHEMBL443 | 0.78 | MAOB (0.73) | NFE2L2MAOBCYP11B1CYP11B2CYP19A1 | |
| (Z)-1,2-Diphenylethene SCHEMBL21847984 | 0.78 | MAOB (0.73) | NFE2L2MAOBCYP11B1CYP11B2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404221-B2 | Methods of arene alkenylation | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-09-02 | — | — | US | disclosed |
| US-20230234900-A1 | METHODS OF ARENE ALKENYLATION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2023-07-27 | — | — | US | disclosed |
| US-20230234900-A1 | METHODS OF ARENE ALKENYLATION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2023-07-27 | — | — | US | disclosed |
| US-20230234900-A1 | METHODS OF ARENE ALKENYLATION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2023-07-27 | — | — | US | disclosed |
| US-8952207-B2 | Copper-catalyzed C—H bond arylation | THE UNIVERSITY OF HOUSTON SYSTEM (US) | 2015-02-10 | — | — | US | disclosed |
| US-20090076266-A1 | COPPER-CATALYZED C-H BOND ARYLATION | THE UNIVERSITY OF HOUSTON SYSTEM (US) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234900-A1 | METHODS OF ARENE ALKENYLATION | CYBB, CBR3, AHR | NFE2L2 102/4885MAOB 157/4885CYP11B1 258/4885 |
| US-12404221-B2 | Methods of arene alkenylation | CYBB, CBR3, AHR | NFE2L2 102/4885MAOB 157/4885CYP11B1 258/4885 |
| US-20090076266-A1 | COPPER-CATALYZED C-H BOND ARYLATION | AOC2, AOC3, DBH | NFE2L2 1368/4885MAOB 65/4885CYP11B1 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.